130 related articles for article (PubMed ID: 33799173)
1. Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
Buckley BJ; Aboelela A; Majed H; Bujaroski RS; White KL; Powell AK; Wang W; Katneni K; Saunders J; Shackleford DM; Charman SA; Cook GM; Kelso MJ; Ranson M
Bioorg Med Chem; 2021 May; 37():116116. PubMed ID: 33799173
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and preliminary evaluation of amiloride analogs as inhibitors of the urokinase-type plasminogen activator (uPA).
Matthews H; Ranson M; Tyndall JD; Kelso MJ
Bioorg Med Chem Lett; 2011 Nov; 21(22):6760-6. PubMed ID: 21978672
[TBL] [Abstract][Full Text] [Related]
3. 6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.
Buckley BJ; Aboelela A; Minaei E; Jiang LX; Xu Z; Ali U; Fildes K; Cheung CY; Cook SM; Johnson DC; Bachovchin DA; Cook GM; Apte M; Huang M; Ranson M; Kelso MJ
J Med Chem; 2018 Sep; 61(18):8299-8320. PubMed ID: 30130401
[TBL] [Abstract][Full Text] [Related]
4. Disruption of Water Networks is the Cause of Human/Mouse Species Selectivity in Urokinase Plasminogen Activator (uPA) Inhibitors Derived from Hexamethylene Amiloride (HMA).
S El Salamouni N; Buckley BJ; Jiang L; Huang M; Ranson M; Kelso MJ; Yu H
J Med Chem; 2022 Feb; 65(3):1933-1945. PubMed ID: 34898192
[TBL] [Abstract][Full Text] [Related]
5. 2-Amidino analogs of glycine-amiloride conjugates: inhibitors of urokinase-type plasminogen activator.
Massey AP; Harley WR; Pasupuleti N; Gorin FA; Nantz MH
Bioorg Med Chem Lett; 2012 Apr; 22(7):2635-9. PubMed ID: 22366654
[TBL] [Abstract][Full Text] [Related]
6. 6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease.
Buckley BJ; Majed H; Aboelela A; Minaei E; Jiang L; Fildes K; Cheung CY; Johnson D; Bachovchin D; Cook GM; Huang M; Ranson M; Kelso MJ
Bioorg Med Chem Lett; 2019 Dec; 29(24):126753. PubMed ID: 31679971
[TBL] [Abstract][Full Text] [Related]
7. Screening of 5- and 6-Substituted Amiloride Libraries Identifies Dual-uPA/NHE1 Active and Single Target-Selective Inhibitors.
Buckley BJ; Kumar A; Aboelela A; Bujaroski RS; Li X; Majed H; Fliegel L; Ranson M; Kelso MJ
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804289
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the regulation of intracellular pH: potential of 5-(N,N-hexamethylene) amiloride in tumour-selective therapy.
Luo J; Tannock IF
Br J Cancer; 1994 Oct; 70(4):617-24. PubMed ID: 7917906
[TBL] [Abstract][Full Text] [Related]
9. Urokinase plasminogen activator as an anti-metastasis target: inhibitor design principles, recent amiloride derivatives, and issues with human/mouse species selectivity.
El Salamouni NS; Buckley BJ; Ranson M; Kelso MJ; Yu H
Biophys Rev; 2022 Feb; 14(1):277-301. PubMed ID: 35340592
[TBL] [Abstract][Full Text] [Related]
10. Antifungal activity of 6-substituted amiloride and hexamethylene amiloride (HMA) analogs.
Vu K; Buckley BJ; Bujaroski RS; Blumwald E; Kelso MJ; Gelli A
Front Cell Infect Microbiol; 2023; 13():1101568. PubMed ID: 36923593
[TBL] [Abstract][Full Text] [Related]
11. Effect of a synthetic inhibitor of urokinase plasminogen activator on the migration and invasion of human cervical cancer cells in vitro.
Wang X; Jiang Z; An J; Mao X; Lin F; Sun P
Mol Med Rep; 2018 Mar; 17(3):4273-4280. PubMed ID: 29328476
[TBL] [Abstract][Full Text] [Related]
12. Hexamethylene amiloride engages a novel reactive oxygen species- and lysosome-dependent programmed necrotic mechanism to selectively target breast cancer cells.
Rowson-Hodel AR; Berg AL; Wald JH; Hatakeyama J; VanderVorst K; Curiel DA; Leon LJ; Sweeney C; Carraway KL
Cancer Lett; 2016 May; 375(1):62-72. PubMed ID: 26944316
[TBL] [Abstract][Full Text] [Related]
13. Amiloride Analogs as ASIC1a Inhibitors.
Leng TD; Si HF; Li J; Yang T; Zhu M; Wang B; Simon RP; Xiong ZG
CNS Neurosci Ther; 2016 Jun; 22(6):468-76. PubMed ID: 26890278
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice.
Jankun J; Keck RW; Skrzypczak-Jankun E; Swiercz R
Cancer Res; 1997 Feb; 57(4):559-63. PubMed ID: 9044824
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic studies of amiloride and its analogs using reversed-phase high-performance liquid chromatography.
Lee C; Tannock I
J Chromatogr B Biomed Appl; 1996 Oct; 685(1):151-7. PubMed ID: 8930763
[TBL] [Abstract][Full Text] [Related]
16. Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride.
Jankun J; Skrzypczak-Jankun E
Cancer Biochem Biophys; 1999 Jul; 17(1-2):109-23. PubMed ID: 10738907
[TBL] [Abstract][Full Text] [Related]
17. Thermosensitization by increasing intracellular acidity with amiloride and its analogs.
Song CW; Kim GE; Lyons JC; Makepeace CM; Griffin RJ; Rao GH; Cragoe EJ
Int J Radiat Oncol Biol Phys; 1994 Dec; 30(5):1161-9. PubMed ID: 7961026
[TBL] [Abstract][Full Text] [Related]
18. In vitro antimicrobial activity of amiloride analogs against Pseudomonas.
Cohn RC; Rudzienski L; Putnam RW
Chemotherapy; 1992; 38(4):232-7. PubMed ID: 1473362
[TBL] [Abstract][Full Text] [Related]
19. Aberrant glomerular filtration of urokinase-type plasminogen activator in nephrotic syndrome leads to amiloride-sensitive plasminogen activation in urine.
Stæhr M; Buhl KB; Andersen RF; Svenningsen P; Nielsen F; Hinrichs GR; Bistrup C; Jensen BL
Am J Physiol Renal Physiol; 2015 Aug; 309(3):F235-41. PubMed ID: 25972510
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumour/metastasis effects of the potassium-sparing diuretic amiloride: an orally active anti-cancer drug waiting for its call-of-duty?
Matthews H; Ranson M; Kelso MJ
Int J Cancer; 2011 Nov; 129(9):2051-61. PubMed ID: 21544803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
